title: In Silico Interaction and Docking Studies Indicate a New Mechanism for PML Dysfunction in Gastric Cancer and Suggest Imatinib as a Drug to Restore Function.
abstract: Gastric cancer as one of the most common cancers worldwide has various genetic and environmental risk factors including Helicobacter pylori (H.pylori) infection. Recently, loss of a tumor suppressor gene named promyelocytic leukemia (PML) has been identified in gastric cancer. However, no mutation has been found in this gene in gastric cancer samples. Cag A H.pylori protein has been shown to exert post transcriptional regulation of some tumor suppressor genes. In order to assess such a mechanism for PML degradation, we performed in silico analyses to establish any interaction between PML and Cag A proteins. In silico interaction and docking studies showed that these two proteins may have stable interactions. In addition, we showed that imatinib kinase inhibitor can restore PML function by inhibition of casein kinase 2.
authors.affiliation: Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran E-mail : ghafourifard@razi.tims.ac.ir.
authors.forename: Zeinab
authors.initials: Z
authors.lastname: Imani-Saber
authors.forename: Soudeh
authors.initials: S
authors.lastname: Ghafouri-Fard
mesh_terms: D000942:Antigens, Bacterial / Q000235:genetics / Q000378:metabolism; D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism; D047390:Casein Kinase II / Q000037:antagonists & inhibitors; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism / Q000821:virology; D016481:Helicobacter Infections / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D016480:Helicobacter pylori / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate / Q000494:pharmacology*; D062105:Molecular Docking Simulation / Q000379:methods; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism*; D000071156:Promyelocytic Leukemia Protein; D054730:Protein Interaction Domains and Motifs / Q000187:drug effects / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D012323:RNA Processing, Post-Transcriptional / Q000187:drug effects / Q000235:genetics; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism*
chemical_list: D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; D047428:Protein Kinase Inhibitors; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C080866:cagA protein, Helicobacter pylori; C070576:PML protein, human; D000068877:Imatinib Mesylate; D047390:Casein Kinase II